Neuren Pharmaceuticals Ltd (ASX:NEU)

Full Year 2024 Neuren Pharmaceuticals Ltd Earnings Call Transcript

Feb 27, 2025 / 01:30 AM GMT

Release Date Price: A$13.23 (-6.83%)

Transcript

Key Points

Positve

Neuren Pharmaceuticals Ltd (NURPF) reported a record year with comprehensive income for shareholders of $166 million, showcasing strong financial performance.
The company has a robust financial foundation, with a pro forma cash position of $AUD359 million, providing significant financial stability and reducing the need for capital raisings.
Neuren Pharmaceuticals Ltd (NURPF) has received $AUD445 million in revenue from DAYBUE over two years, with a 100% margin contributing directly to pre-tax profit.
The company is optimistic about future growth opportunities, particularly with the NNZ-2591 opportunity, which has the potential to create significant value.
Acadia's partnership is strong, with positive outcomes in the commercial phase and plans for expansion into new markets, including Europe, and Japan, enhancing long-term growth prospects. Additionally, DAYBUE was approved in Canada in 2024.

Negative

The company's share price has not reflected its strong financial performance, with management expressing dissatisfaction with its current valuation.
There are concerns about the persistence rate of DAYBUE, with only 50% of patients remaining on the drug after 12 months, which could impact long-term sales.
The company faces challenges in expanding its market reach, particularly in accessing the 70% of diagnosed patients who have not yet tried DAYBUE.
Neuren Pharmaceuticals Ltd (NURPF) is still awaiting FDA alignment on primary efficacy endpoints for its phase 3 trials, which could impact the timeline for trial commencement.
There is uncertainty regarding the impact of potential changes to Medicare and Medicaid on DAYBUE's access and sales, which could affect future revenue.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

NEU.AX - Neuren Pharmaceuticals Ltd
Full Year 2024 Neuren Pharmaceuticals Ltd Earnings Call
Feb 28, 2025 / 01:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon. Welcome to Neurons Investor webinar to discuss 2024 calendar year full year results. My name is Jerry Zel, Chief Business Officer at Neuron.

Joining me on the call today is John Pilcher, CEO of Neuron. John will make the presentation and we'll be available for Q&A. You can use the QNA button to submit your questions.

Before we start, I would like to remind everyone that we'll be making forward-looking statements during today's call, which are subject to risks and uncertainties that may lead to different outcomes. I'll now turn the call over to John to start the presentation.

--------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.